A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and: Neisseria meningitidis outer membrane vesicles

Darielys Santana-Mederos, Rocmira Perez-Nicado, Yanet Climent, Laura Rodriguez, Belinda Sanchez Ramirez, Sonia Perez-Rodriguez, Meybi Rodriguez, Claudia Labrada, Tays Hernandez, Marianniz Diaz, Ivette Orosa, Ubel Ramirez, Reynaldo Oliva, Raine Garrido, Felix Cardoso, Mario Landys, Roselyn Martinez, Humberto Gonzalez, Tamara Hernandez, Rolando Ochoa-AzzeJose L. Perez, Juliet Enriquez, Nibaldo Gonzalez, Yenicet Infante, Luis A. Espinosa, Yassel Ramos, Luis Javier González, Carmen Valenzuela, Ana Victoria Casadesus, Briandy Fernandez, Gertrudis Rojas, Beatriz Pérez-Massón, Yaima Tundidor, Ernesto Bermudez, Claudia A. Plasencia, Tammy Boggiano, Eduardo Ojito, Fabrizio Chiodo, Sonsire Fernandez, Dagmar Garcia-Rivera, Cheng Fang, Guang-Wu Chen, Daniel G. Rivera, Yury Valdes-Balbin, Dagmar Garcia-Rivera, Vicente Verez Bencomo

Research output: Contribution to journalArticleAcademicpeer-review

7 Citations (Scopus)


SARS-CoV-2 infection is mediated by the interaction of the spike glycoprotein trimer via its receptor-binding domain (RBD) with the host's cellular receptor. Vaccines seek to block this interaction by eliciting neutralizing antibodies, most of which are directed toward the RBD. Many protein subunit vaccines require powerful adjuvants to generate a potent antibody response. Here, we report on the use of a SARS-CoV-2 dimeric recombinant RBD combined with Neisseria meningitidis outer membrane vesicles (OMVs), adsorbed on alum, as a promising COVID-19 vaccine candidate. This formulation induces a potent and neutralizing immune response in laboratory animals, which is higher than that of the dimeric RBD alone adsorbed on alum. Sera of people vaccinated with this vaccine candidate, named Soberana01, show a high inhibition level of the RBD-ACE2 interaction using RBD mutants corresponding to SARS-CoV-2 variants of concern and wild-type expressed using the phage display technology. To our knowledge, this is the first time that the immunostimulation effect of N. meningitidis OMVs is evaluated in vaccine candidates against SARS-CoV-2.
Original languageEnglish
Pages (from-to)242-249
Number of pages8
JournalRSC Chemical Biology
Issue number2
Publication statusPublished - 1 Feb 2022

Cite this